Table 6.
Prognostic significance of the expression of glypicans on the relapse-free survival of breast cancer patients stratified by triple-negative status
| Genes | Triple status (ER/PR/HER2) | Relapse free survival | ||
|---|---|---|---|---|
| Number of cases | HR 95% CI | P value | ||
| GPC1 | Negative | 255 | 1.8 (1.16–2.8) | 0.008 |
| GPC2 | Negative | 161 | 1.38 (0.8–2.39) | 0.24 |
| GPC3 | Negative | 255 | 1.05 (0.68–1.6) | 0.84 |
| GPC4 | Negative | 255 | 1.06 (0.7–1.62) | 0.78 |
| GPC5 | Negative | 255 | 1.1 (0.72–1.69) | 0.65 |
| GPC6 | Negative | 161 | 1.47 (0.85–2.56) | 0.16 |
Bold typing of P values indicates a significance level P < 0.05
HR Hazard ratio, CI confidence interval